At present, it remains premature to conclude whether these combination therapies are effective or not, but early clinical trials with a limited number of melanoma patients reported severe subacute/late complications when treated with IFN-α+RT [47,48], casting doubts or requiring precautions when combining them in the clinic. The gene discussed is IFNA1; the disease is melanoma.